Clinical Trial Update: Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

This is a Phase 2 clinical trial update for a combination of anastrozole, fulvestrant, and abemaciclib in HR-positive, HER2-negative metastatic breast cancer. T…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Hormone Receptor-positive Breast Cancer

Drugs mentioned

• ARIMIDEX (anastrozole)
• Faslodex (fulvestrant)
• VERZENIO (ABEMACICLIB)

Snippet

Sponsor: University of California, Irvine | Conditions: Breast Cancer, Metastatic Breast Cancer | Phase 2 | Status: RECRUITING